ClinicalTrials.gg
CompletedNCT05698823Updated Mar 19, 2026

Regular Home-use of Dual-light Photodynamic Therapy in the Management of Chronic Stage III-IV Periodontitis

An interventional study of Lumoral Treatment in Periodontitis Chronic Generalized Moderate and Periodontitis Chronic Generalized Severe, sponsored by Koite Health Oy. Completed at 1 site in Lithuania. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Koite Health Oy · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study is designed to determine the efficacy of the Lumoral method in chronic periodontitis with a targeted group of stage III and IV periodontitis.

Improved supragingival plaque control can help to also sustain the subgingival plaque management in the long term.

In addition, the method might have a photobiomodulation effect on periodontal tissues.

Read the detailed description

The Lumoral Treatment is a CE-marked medical device developed to provide a potent, targeted antibacterial action on dental plaque in a home environment. The device mechanism of action is antibacterial photodynamic therapy (aPDT). The device is used by swishing a specially designed mouth rinse that strongly adheres to dental plaque. The plaque-adhered photoactive mouth rinse can be activated by a simple-to-use light applicator. Preliminary results have shown promising anti-inflammatory responses in addition to plaque reduction.

02

Conditions studied

  • Periodontitis Chronic Generalized Moderate
  • Periodontitis Chronic Generalized Severe

Browse trials for

Keywords

  • Lumoral
  • Lumorinse
  • Periodontitis
  • Anti-bacterial photodynamic therapy
  • aPDT
  • Plaque
  • aMMP-8
  • Photobiomodulation
03

In context

Periodontitis

1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.

This study's enrollment of 56 is above the median of 44 across 850 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Koite Health Oy is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Periodontal disease stage III-IV, according to criteria the American Academy of Periodontology (AAP) with at least 3 mm interdental clinical attachment level (CAL) in the site of greatest loss.
  • ≥ 18 years old
  • Presence of ≥20 teeth, including implants
  • Agreement to participate in the study and to sign a written consent form
  • Able to co-operate with the treatment protocol and avoid any other oral hygiene measures outside of the study protocol

Exclusion criteria

Exclusion Criteria:

  • Grade A or C periodontitis
  • Presence of any physical limitation or restriction that might restrict Lumoral use
  • Pregnancy or lactation
  • Active smoking
  • Medicated diabetes mellitus (DM)
  • Any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of periodontal disease
  • Use of antibiotics within 4 weeks week prior study
  • Periodontal treatment within 3 months prior study
  • Removable major prosthesis or major orthodontic appliance
  • A need for a hopeless teeth extraction, or open cavities in need for immediate endodontic treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Study group

    A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. The study group shall receive the Lumoral treatment -device, Lumorinse -tablets and instructions for their use. All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss.

    Device: Lumoral Treatment

  • No intervention
    Control group

    A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss.

Interventions

  • DeviceLumoral Treatment

    The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.

06

What researchers measure

Primary outcomes

  1. Bleeding on probing (BOP)

    Improvement in bleeding on probing (BOP) * A full-mouth assessment at six sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) * Gingival bleeding is considered as positive if bleeding occurs within 15 seconds after gentle probing with a probe at the sulcus * Dichotomous scoring to each site of the tooth as bleeding "1 present" and "0 absent" * BOP is reported as the percentage (%) of sites with positive findings * Calculation formula: number of bleeding sites/ 6 times number of teeth

    Time frame: 6 months

Secondary outcomes

  1. Active matrix metalloproteinase 8 (aMMP-8)

    Change in periodontal inflammation marker aMMP-8

    Time frame: 6 months

  2. Visible plaque index (VPI)

    Change in visible plaque index (VPI)

    Time frame: 6 months

  3. Probing pocket depth (PPD)

    Change in probing pocket depth (PPD)

    Time frame: 6 months

  4. Clinical attachment level (CAL)

    Change in clinical attachment level (CAL)

    Time frame: 6 months

  5. Deep periodontal pockets (over 4 mm)

    Change in the number of deep periodontal periodontal pockets (over 4 mm)

    Time frame: 6 months

  6. Periodontal microbiological flora

    Change in periodontal microbiological flora during the study period

    Time frame: 6 months

  7. Additional visits

    Number of additional visits due to periodontitis status between 2nd and 3rd follow-up visits

    Time frame: 6 months

  8. OHIP-14

    Patient related objectives: Oral-related quality of life measurement (OHIP-14) questionnaire

    Time frame: 6 months

Other outcomes

  1. Device-related adverse event

    Absence of device-related serious adverse events or any patterns of device-related adverse events graded as moderate

    Time frame: 6 months

07

Study locations

1 site
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Dental and Oral Pathology
    Kaunas, 50161, Lithuania
08

References and documents

Publications

  • Kassebaum NJ, Bernabe E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of severe periodontitis in 1990-2010: a systematic review and meta-regression. J Dent Res. 2014 Nov;93(11):1045-53. doi: 10.1177/0022034514552491. Epub 2014 Sep 26. PubMed 25261053 ↗
  • Kassebaum NJ, Smith AGC, Bernabe E, Fleming TD, Reynolds AE, Vos T, Murray CJL, Marcenes W; GBD 2015 Oral Health Collaborators. Global, Regional, and National Prevalence, Incidence, and Disability-Adjusted Life Years for Oral Conditions for 195 Countries, 1990-2015: A Systematic Analysis for the Global Burden of Diseases, Injuries, and Risk Factors. J Dent Res. 2017 Apr;96(4):380-387. doi: 10.1177/0022034517693566. PubMed 28792274 ↗
  • Lang NP, Suvan JE, Tonetti MS. Risk factor assessment tools for the prevention of periodontitis progression a systematic review. J Clin Periodontol. 2015 Apr;42 Suppl 16:S59-70. doi: 10.1111/jcpe.12350. PubMed 25496279 ↗
  • Nikinmaa S, Moilanen N, Sorsa T, Rantala J, Alapulli H, Kotiranta A, Auvinen P, Kankuri E, Meurman JH, Patila T. Indocyanine Green-Assisted and LED-Light-Activated Antibacterial Photodynamic Therapy Reduces Dental Plaque. Dent J (Basel). 2021 May 3;9(5):52. doi: 10.3390/dj9050052. PubMed 34063662 ↗
  • Slade GD. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol. 1997 Aug;25(4):284-90. doi: 10.1111/j.1600-0528.1997.tb00941.x. PubMed 9332805 ↗

Related links

Individual participant data

Plan to share: No — The IPD will only be administered by the researchers that are listed in the CIP.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Dec 2025, 30 months.

Of 498 interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Jan 26, 2023
StartActual
Jun 6, 2023
Primary completionActual
Dec 12, 2025
CompletionActual
Jan 12, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05698823
Lead sponsor
Koite Health Oy
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Jun 6, 2023
Primary completion
Dec 12, 2025
Completion
Jan 12, 2026
Last update
Mar 19, 2026

Study contacts

Timo Sorsa, Professor
study director · University of Helsinki
Tommi Pätilä, Docent
study chair · Koite Health
Ingrida Marija Pacauskiene, Doctor
principal investigator · Lithuanian University of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion